GSK application for preliminary injunction withdrawn just before Cologne Court of appeals was to rule in the case

  • GlaxoSmithKline withdraws application for preliminary injunction on German marketing and distribution of Sandoz’s award-winning AirFluSal® Forspiro®
  • GSK application withdrawn shortly before Cologne Court of Appeals was due to rule in the case, restoring German patient access to AirFluSal
  • Sandoz continues to roll out its innovative and cost-effective respiratory inhaler, co-developed with patients, in Europe and beyond

Holzkirchen, June 16, 2014: Pharmaceutical company GlaxoSmithKline has withdrawn its application for a preliminary …

/by

Sandoz France launches generic Nasonex® nasal spray, the first generic nasal corticoid on the French market

  • French launch is latest milestone in roll-out of Sandoz respiratory portfolio – a key pillar of its strategy to bring differentiated generics to patients and payors worldwide
  • Mometasone Sandoz® is first French specialty generic medicine indicated for treatment of a respiratory condition together with an inhaler
  • Allergic rhinitis affects up to 25% of the population of Western Europe annually

Levallois-Perret, June 2, 2014 – Sandoz, the generic pharmaceuticals division of Novartis, today announces the launch in France of Mometasone Sandoz®, …

/by

Sandoz enhances strategic relationship with Upsher-Smith through marketing agreement for potassium chloride products

Princeton, New Jersey, June 3, 2014 – Sandoz today announced an agreement with Upsher-Smith to obtain exclusive US distribution rights for its branded potassium chloride line of products, Klor-Con®, and market them under the Sandoz name, enhancing its strategic relationship.

“This agreement expands and strengthens our current relationship with Upsher-Smith and helps us create a leading potassium chloride business,” said Peter Goldschmidt, President of Sandoz Inc. “With our extensive distribution system, we will be able to improve patient access to these products, …

/by

Sandoz associates join Novartis Community Partnership Day 2014

Holzkirchen, May 15, 2015 – More than 19,000 Novartis associates worldwide volunteer for local causes on Community Partnership Day

Novartis associates across 55 countries engaged in local volunteer efforts to support their communities in celebration of the company’s annual Community Partnership Day (CPD).

May 8th of this year marked the 18th Community Partnership Day, commemorating the 1996 creation of Novartis as a global leader in healthcare.

There is strong participation from all Novartis divisions in 2014, including Sandoz. Here we feature some …

/by

Sandoz launches generic version of key anti-depressant Cipralex® in several European countries

Holzkirchen, June 4, 2014 – Sandoz, the generic pharmaceuticals division of Novartis, today announced the launch in several European countries of generic escitalopram, an affordable and high-quality version of reference product Cipralex®.

The Sandoz product, which is available in all strengths approved for the reference product (5mg, 10mg, 15mg and 20mg), was launched initially in countries including Belgium, France, Germany, Italy, Sweden and Switzerland.

Nick Haggar, Head of Sandoz Western Europe, Middle East and Africa, said: “Sandoz is already a regional …

/by

Sandoz launches generic version of key anti-depressant Cipralex® in several European countries

Holzkirchen, June 4, 2014 – Sandoz, the generic pharmaceuticals division of Novartis, today announced the launch in several European countries of generic escitalopram, an affordable and high-quality version of reference product Cipralex®.

The Sandoz product, which is available in all strengths approved for the reference product (5mg, 10mg, 15mg and 20mg), was launched initially in countries including Belgium, France, Germany, Italy, Sweden and Switzerland.

Nick Haggar, Head of Sandoz Western Europe, Middle East and Africa, said: “Sandoz is already a regional …

/by

Sandoz launches AirFluSal® Forspiro® in South Korea

Seoul, May 14 2014 – Sandoz Korea announces that it is launching today AirFluSal® Forspiro®, an innovative new inhaler for patients with asthma and/or chronic obstructive pulmonary disease (COPD).

​The product was first approved in Denmark in December, 2013 with subsequent approvals in Germany, Belgium, Sweden, Norway, Hungary, Romania, Bulgaria and South Korea.

“We are pleased to launch AirFluSal® Forspiro® in South Korea. This is a milestone in our strategy of bringing our world class innovative inhaler to patients in Korea,” said Sujun Park, Country Head of …

/by

Court supports access to Sandoz’s innovative respiratory device in Norway

We are pleased that a court in Norway has denied GSK’s request to restrict access to Sandoz’s AirFluSal® Forspiro® in Norway. AirFluSal® Forspiro® provides patients with asthma and/or COPD with an award-winning innovative device for delivering the proven combination of salmeterol (a long-acting inhaled ß2-agonist) and fluticasone (an inhaled corticosteroid). We look forward to continuing to provide patients access to this important device. The decision is still subject to appeal.

About Sandoz

Sandoz, the generic pharmaceuticals division of Novartis, is a global …

/by

Sandoz recognizes World Asthma Day 2014

Today Sandoz recognizes World Asthma Day. World Asthma Day is an annual event organized by the Global Initiative for Asthma (GINA) with the goal of improving asthma awareness and care around the world. This year’s theme is, “It’s time to control asthma.”

A chronic, inflammatory lung disease, asthma is currently the most common non-communicable disease amongst children worldwide. GINA estimates that there are 300 million sufferers worldwide and there may be an additional 100 million people living with asthma by 2025.

Asthma is characterized by airway obstruction which results in …

/by

Sandoz launches generic version of Differin® Gel, 0.3%

Princeton, New Jersey, April 28, 2014 – Sandoz today announced the US market introduction of its adapalene 0.3% gel, a generic version of Galderma Laboratories’ Differin® Gel, 0.3%.

Adapalene gel is a retinoid, indicated for the topical treatment of acne vulgaris in patients 12 years of age and older. Acne vulgaris is a condition that affects nearly 85% of the US population at some point in their life.1

“Sandoz is proud to market a high-quality, affordable generic version of this important topical therapy,” said Peter Goldschmidt, President of Sandoz …

/by